Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalent Inc
(NY:
CTLT
)
59.55
-0.26 (-0.43%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Catalent Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
August 16, 2024
A small telemedicine company just entered the weight loss race.
Via
The Motley Fool
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
June 21, 2024
Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.
Via
Benzinga
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
June 01, 2024
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
May 28, 2024
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.
Via
The Motley Fool
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
May 24, 2024
Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.
Via
Benzinga
CTLT Stock Earnings: Catalent Misses EPS, Misses Revenue for Q3 2024
May 09, 2024
CTLT stock results show that Catalent missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
Via
InvestorPlace
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
May 02, 2024
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly.
Via
Benzinga
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
April 12, 2024
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled...
Via
Benzinga
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
April 04, 2024
Via
Benzinga
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
March 26, 2024
All three of these high-flying stocks could have more room to run.
Via
The Motley Fool
(CTLT) - Analyzing Catalent's Short Interest
February 28, 2024
Via
Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Catalent
February 20, 2024
Via
Benzinga
Earnings Outlook For Catalent
February 08, 2024
Via
Benzinga
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Did Novo Nordisk Just Get a Jump on Eli Lilly?
March 19, 2024
A recent FDA announcement may have just put one company in the lead.
Via
The Motley Fool
Exposures
Product Safety
The Top 3 Pharma Stocks to Buy in March2024
March 09, 2024
Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.
Via
InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
March 08, 2024
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect significant weight loss and cardiovascular benefits. Phase 2 trial begins in late...
Via
Benzinga
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
March 06, 2024
Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as Eli Lilly and Novo Nordisk address production bottlenecks amid rising...
Via
Benzinga
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
March 05, 2024
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
Via
The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
March 01, 2024
U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones.
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.
Via
Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
February 26, 2024
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Via
Benzinga
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
February 14, 2024
Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...
Via
Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
February 11, 2024
Even more revenue is on the way from additional sales of Wegovy.
Via
The Motley Fool
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
February 10, 2024
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.
Via
The Motley Fool
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
February 09, 2024
The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory.
Via
Benzinga
Earnings Scheduled For February 9, 2024
February 09, 2024
Companies Reporting Before The Bell • TELUS (NYSE:TU) is expected to report quarterly earnings at $0.23 per share on revenue of $5.24 billion.
Via
Benzinga
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
February 08, 2024
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company.
Via
Benzinga
Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns
February 07, 2024
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.